Pfizer's future depends on IT transformation


Become An Insider

Sign up now and get free access to hundreds of Insider articles, guides, reviews, interviews, blogs, and other premium content from the best tech brands on the Internet: CIO, CSO, Computerworld, InfoWorld, IT World and Network World Learn more.

Chip-munching, sedentary people have made Pfizer a bundle of money. Lipitor, a drug that lowers cholesterol, ranks as Pfizer's top-selling pill for 12 years running. A blockbuster among blockbusters, Lipitor brought in $10.7 billion, or 16%, of the company's $67.8 billion in revenues last year.

This month, though, Pfizer loses a crucial patent protection on Lipitor and, with it, the exclusive right to make and sell the drug. Competitors are ready to swoop in with generic versions and swoop out with many billions of dollars.

In the next four years, patents on six other key Pfizer medicines are due to expire. Viagra, the drug of choice for treating erectile dysfunction, is another huge product for Pfizer. The company went to court this summer to fight for control of it after a challenge from a generics maker. To Pfizer's relief, a judge ruled that a key Viagra patent is valid until 2019.

To continue reading, please begin the free registration process or sign in to your Insider account by entering your email address:
What’s wrong? The new clean desk test
You Might Like
Join the discussion
Be the first to comment on this article. Our Commenting Policies